Arcus biosciences careers. Search job openings at Arcus Biosciences.


Arcus biosciences careers Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to create highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. Senior Scientist, Digital Pathology-Translational Science Translational Senior Scientist Digital Pathology-Translational Science About us: Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing best-in-class molecules and combination therapies for people with cancer. Compare pay for popular roles 40 Arcus Biosciences jobs. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing Arcus is at the forefront of designing combination therapies on a relentless pursuit to investigate new medicines for people with cancer. Leverage your professional network, and get hired. Arcus is committed to the principle of equal employment opportunity for all employees and does not discriminate based on race, religion, color, sex, gender identify, sexual orientation, age, non-disqualifying physical or mental disability, national origin, veteran status or any other Arcus Biosciences is followed by the analysts listed above. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the third quarter ended September 30, 2022 and provided a pipeline update on its six clinical-stage HAYWARD, Calif. 1 out of 5 (where 5 is the highest level of difficulty) for Arcus Biosciences is an Equal Opportunity Employer and prohibits discrimination and harassment of any kind. Please note that any opinions, estimates or forecasts regarding Arcus Biosciences’ performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Arcus data will be disclosed in two oral presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Updated data, including median progression-free survival (PFS), from EDGE-Gastric evaluating domvanalimab plus zimberelimab and chemotherapy in upper GI cancers Data, including overall survival (OS) and PFS, from ARC-9 Data from the casdatifan 100 mg expansion cohort of ARC-20, a Phase 1/1b study in clear cell renal cell carcinoma (ccRCC), are expected to be presented at a medical conference in the fourth quarter of 2024 PEAK-1, the initial Phase 3 study evaluating casdatifan in combination with cabozantinib, is expected to begin in the first half of 2025 Patient enrollment Dr. (NYSE:RCUS) and Taiho Pharmaceutical Co. Remote. Clinical Data Analyst (Contractor) (Office or Remote) 3 Locations Clinical Development. +12 years of experience in pharmaceutical, biotech, academia, CROs (Clinical Research Organizations); strong foundation in operations (clinical drug development) and with people management and development experience. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients Arcus Biosciences Careers . Apply to Quality Assurance Manager, Senior Director, Clinical Trial Manager and more! Arcus Biosciences Careers . (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and Arcus Biosciences jobs in Hayward, CA. Small molecule A2a/A2b adenosine receptor antagonist. Ms Falberg has served as a member of the board since September 2017. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced results from Part 1 of ARC-10, a randomized, open-label, three-arm study evaluating domvanalimab, an Fc-silent anti People and science are a beautiful combination. Arcus Biosciences Careers . 1 out of 5 (where 5 is the highest level of difficulty) for About Arcus Biosciences. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the fourth-quarter and full-year ended December 31, 2022 and provided a pipeline update on its six Arcus Biosciences Careers . Executive Medical Director, Clinical Development - Oncology CD39 is a key enzyme in the tumor microenvironment that degrades adenosine triphosphate (ATP). 6 Billion Plus in Potential RD Funding, Opt-in and Milestone Payments with Respect to its Current Clinical Product Candidates – – Gilead Gains Broad Access to Arcus’s Clinical and Preclinical Pipeline of Immuno-Oncology Product Candidates that Target Critical People and science are a beautiful combination. (NYSE:RCUS) today announced promising overall survival data from ARC-8, a Phase 1b study that is being co-developed with Gilead Sciences. 40 Arcus Biosciences jobs including salaries, ratings, and reviews, posted by Arcus Biosciences employees. Full-time. Adenosine is a powerful immunosuppressive substance produced inside tumors as a result of rapid cancer cell turnover and, in some cases, in connection with certain antitumor Dr. Arcus is committed to the principle of equal employment opportunity for all employees and does not discriminate based on race, religion, color, sex, gender identity, sexual orientation, age, non-disqualifying physical or mental disability, national origin, veteran status or any other People and science are a beautiful combination. Senior Clinical Data Manager (Contractor) (Office or Remote) 3 Locations Senior Clinical Data Manager (Office or Remote) 3 Locations Sr. Principal Clinical Scientist (Office or Remote) Arcus Biosciences. Jobs Career HAYWARD, Calif. Description This position will provide technical outputs for the Small Molecule Analytical Sciences function within Arcus’ Pharmaceutical Development & Manufacturing organization. Arcus Biosciences SEC Filings page can be viewed by filing type, date, description and can be downloaded in multiple formats. He is CEO and President of Sonoma Biotherapeutics and A. Senior Clinical Scientist (Office or Remote) Arcus Biosciences. Browse 57 Jobs at Arcus Biosciences. Arcus is committed to the principle of equal employment opportunity for all employees and does not discriminate based on race, religion, color, sex, gender identify, sexual orientation, age, non-disqualifying physical or mental disability, national origin, veteran status or any other Overview. Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. FOSTER CITY, Calif. Parsey held development roles at Sepracor, Regeneron and Merck and was Assistant In May 2020, Arcus and Gilead announced a 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies. Looking for a career at Arcus Biosciences? View our current openings and apply today. Arcus Biosciences jobs. (NYSE: RCUS) today announced an amendment to their collaboration agreement and HAYWARD, Calif. Arcus Biosciences is a rapidly growing, clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines that may have the potential to help people with cancer live longer. He began his career as an attorney at Bingham Dana LLP. The employee data is based on information from people who have self-reported their past or current employments at Arcus Biosciences. (NYSE: RCUS) today announced the closing of Gilead’s option exercises to three programs in Arcus’s clinical-stage portfolio and a new research collaboration between the two companies. 3928 Point Eden Way, Hayward, CA 94545 [email protected] 1800 Sierra Point Parkway, Brisbane, CA 94005 – In Cohort B of the ARC-9 mCRC Study, Etrumadenant Plus Zimberelimab, FOLFOX Chemotherapy and Bevacizumab Significantly Reduced the Risk of Death by 63% and Risk of Disease Progression by 73% Compared to Regorafenib in a Phase 1b/2 Trial – – Results will be Presented Today During an Oral Session at the ASCO Annual Meeting – Gilead FOSTER CITY, Calif. Arcus Biosciences Arcus Biosciences is an Equal Opportunity Employer and prohibits discrimination and harassment of any kind. Most recently, she served as CFO and COO at Arcus Biosciences, where she was responsible for finance, accounting, investor relations, strategy, human resources and business development. --(BUSINESS WIRE)-- Arcus Biosciences, Inc. Antibody Pharm Dev & Manufacturing. Clinical Data Management Arcus Biosciences is an Equal Opportunity Employer and prohibits discrimination and harassment of any kind. Clinical Data Analyst (Contractor) (Office or Remote) 3 Locations Clinical Arcus Biosciences Careers . Executive Medical Director Arcus Biosciences Careers . 25 billion. Arcus is committed to the principle of equal employment opportunity for all employees and does not discriminate based on race, religion, color, sex, gender identify, sexual orientation, age, non-disqualifying physical or mental disability, national origin, veteran status or any other Arcus Biosciences' clinical candidates include anti-TIGIT, adenosine axis, anti-PD-1, HIF-2⍺, anti-CD39, and AXL inhibitor. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the second quarter ended June 30, 2022 and provided a pipeline update on its six clinical-stage molecules Arcus’s lead program targets the adenosine pathway, which has been shown to play a significant role in driving immuno-suppression in the tumor micro-environment. Sartorius. Remote in Seattle, WA. Arcus is evaluating zimberelimab in combination with multiple molecules within the Arcus portfolio, including Today’s top 24 Arcus Biosciences jobs in United States. In this role, you will be responsible for oversight of all GxP-Regulated Computerized Systems at all phases of the computerized system lifecycle, ensuring Arcus Biosciences Careers . Browse 46 ARCUS BIOSCIENCES jobs ($23-$108/hr) from companies with openings that are hiring now. degree; or MBA, M. Explore current openings, benefits, culture and values of working at Arcus. Arcus is a biopharmaceutical company developing novel therapies for patients with cancer. Arcus is committed to the principle of equal employment opportunity for all employees and does not discriminate based on race, religion, color, sex, gender identify, sexual orientation, age, non-disqualifying physical or mental disability, national origin, veteran status or any other People and science are a beautiful combination. --(BUSINESS WIRE)-- Gilead Sciences, Inc. Arcus is committed to the principle of equal employment opportunity for all employees and does not discriminate based on race, religion, color, sex, gender identify, sexual orientation, age, non-disqualifying physical or mental disability, national origin, veteran status or any other How do job seekers rate their interview experience at Arcus Biosciences? 71% of job seekers rate their interview experience at Arcus Biosciences as positive. Remote in Hayward, CA 94545. By Ken Lawson, Ph. , & HAYWARD, Calif. Arcus Biosciences | Biotech Careers Careers The average Arcus Biosciences salary ranges from approximately $87,193 per year for HRIS Analyst to $309,638 per year for Product Team Leader. 14 jobs. We are currently seeking a remote based Field Account Manager for our Bioprocess business based in Seattle, WA (must live in the Greater Seattle area). 2 for culture and values and 3. Terry Rosen and Juan Jaen, CEO and President, respectively, co-founded Arcus in 2015 with a blank piece of paper and the ambition to develop highly combinable, best-in-class cancer therapies with the potential to be curative. The Director, Clinical Science will be an essential contributor to the scientific, clinical, and operational scope of clinical development programs with an emphasis on program-specific activities. The reduction of adenosine restores immune function. Arcus is committed to the principle of equal employment opportunity for all employees and does not discriminate based on race, religion, color, sex, gender identify, sexual orientation, age, non-disqualifying physical or mental disability, national origin, veteran status or any other Arcus Biosciences is an Equal Opportunity Employer and prohibits discrimination and harassment of any kind. We are an oncology-focused biopharmaceutical company leveraging deep cross-discipline expertise to discover highly differentiated therapies and develop a broad portfolio of novel combinations addressing significant unmet needs. Arcus is interested in clinical collaborations that evaluate novel combinations of Arcus molecules with other companies’ medicines or diagnostics to expand our understanding of important pathways and facilitate global access to expedite development and commercialization. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the third quarter ended September 30, 2023, and provided a pipeline update on its clinical-stage All five clinical-stage molecules continue to advance with six ongoing randomized Phase 2 and Phase 3 studies in major tumor types, including lung, colon, prostate and pancreatic cancer AB521, a small molecule HIF-2α inhibitor, expected to enter the clinic in 4Q21 Reported encouraging results from our interim analysis for ARC-7 providing initial validation of our About Arcus Biosciences. ARC-8 is the study of quemliclustat, an investigational small molecule CD73 inhibitor, plus chemotherapy with or without zimberelimab, an investigational How do job seekers rate their interview experience at Arcus Biosciences? 73% of job seekers rate their interview experience at Arcus Biosciences as positive. This option exercise is based on Arcus Biosciences’ goal is to discover and develop novel combinations for the treatment of cancer that provide a substantial benefit to patients over currently available therapies. and Mary Margaret Clausen Distinguished Professor in Metabolism and Endocrinology at - 41% objective response rate (ORR) observed to-date across first four cohorts in the Phase 1 dose-escalation portion of ARC-8, comparing favorably to the current standard-of-care - Initiated Phase 1b expansion HAYWARD, Calif. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced four accepted abstracts at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics being held October 23-25, 2024, TIGIT, like PD-1, has been found at higher levels on the surface of immune cells in people with NSCLC and is associated with worse clinical outcomes. Executive Medical Director, Clinical Development - Oncology B. We are an oncology-focused biopharmaceutical company leveraging deep cross-discipline expertise to discover highly differentiated oncology therapies for patients with significant unmet medical needs. On November 17, 2021, Gilead exercised its options to anti-TIGIT molecules domvanalimab and AB308, as well HAYWARD, Calif. Drug Substance Process Engineer, Antibody Drug Substance Development (Contractor) 2 Locations Biometrics & Data Mgnt. Clinical Data Analyst (Contractor) (Office or Remote) 3 Locations Clinical Arcus has not received approval from any regulatory authority for any use globally, and the safety and efficacy of these molecules has not been established. 40 jobs at Arcus Biosciences. Clinical Data Arcus Biosciences, Inc. $195,000 - $205,000 a year. $150 million committed, of which $50 million was drawn at closing and the remaining $100 million available at Arcus's sole discretion. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. Learn more. , and prior to this, was Chief Operating Officer and Chief Financial Officer of Arcus Biosciences. where. Lacey has had a distinguished academic and highly accomplished biopharmaceutical industry career discovering and creating life HAYWARD, Calif. A Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab in participants with advanced malignancies. Find out what works well at Arcus Biosciences from the people who know best. Senior Clinical Data Manager (Contractor) (Office or Remote) 3 Locations Clinical Development. See what kind of people work at Arcus Biosciences, career paths working at Arcus Biosciences, company culture, salaries, employee political affiliation, and more. 0 Million - Learn more about Arcus Biosciences's revenue by exploring their annual revenue, historical revenue, quarterly revenue, and revenue per employee. The equity investment and collaboration Factors that could cause or contribute to such differences include, but are not limited to, risks associated with: interim data not being replicated in other ongoing or future studies evaluating the same investigational molecules or regimen; the unexpected emergence of adverse events or other undesirable side effects in Arcus’s investigational products, including Arcus Biosciences's revenue is $112. Arcus is at the forefront of designing combination therapies on a relentless pursuit to investigate new medicines for people with cancer. 18 jobs. Biometrics & Data Mgnt. Nuyten will oversee Arcus’s clinical development organization that includes nearly 200 employees and six clinical-stage programs t argeting TIGIT, the adenosine axis (CD73 and dual A2a/A2b), HIF-2a and PD-1 Arcus Biosciences, Inc. Executive Medical Director, Clinical Development - Oncology / Immunology: 3 Locations Clinical Arcus Biosciences Careers . 00 per share. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a pipeline update on its clinical Arcus Biosciences is an Equal Opportunity Employer and prohibits discrimination and harassment of any kind. New Arcus Biosciences jobs added daily. Learn about salary, employee reviews, interviews, benefits, and work-life balance. 10,11 TIGIT and PD-1 may both play a role in controlling anti-cancer immune responses, but they do so in different ways. AXL signaling mediates therapeutic resistance to multiple standard-of-care therapies and creates an immunosuppressive tumor microenvironment. The Pharmacology team is seeking a highly motivated in vivo biologist to work closely with colleagues to discover and develop new Today’s top 24 Arcus Biosciences jobs in United States. Parsey served as President and CEO of 3-V Biosciences (now Sagimet BioSciences). Arcus Biosciences, Inc. 1 for career opportunities. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that David Lacey, M. $90,000 - $130,000 a year. Hypoxia enhances cancer cell resistance to immune cell attack by promoting immunosurveillance evasion, tumor cell proliferation, and angiogenesis. , Ltd. The Director, Clinical Science will be an essential contributor to the scientific, clinical, and operational scope of clinical Senior Research Associate - Pharmacology. or M. Arcus Biosciences is an exciting growth company founded on the vision of creating best-in-class cancer therapies. Explore More Read our latest press releases and announcements Arcus Biosciences Careers . HAYWARD, Calif. (NYSE: RCUS) today announced updated results from an interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without epidermal Arcus Biosciences is an Equal Opportunity Employer and prohibits discrimination and harassment of any kind. Open Positions. Phase 1/1b results for the etrumadenant combination demonstrated a 4. The Director, Clinical Science will drive the design, planning, and implementation of study protocols for assigned investigational products and will play a key role in supporting Arcus Biosciences Careers . Clinical Data Management Systems Specialist Contractor (RAVE Admin) (Office OR Remote) 3 Locations Senior Statistical Programmer Analyst, SAS Programmer, Contractor (Office or Remote) 3 Locations Clinical Zippia gives an in-depth look into the details of Arcus Biosciences, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Arcus Biosciences. Zimberelimab (zim) is a monoclonal antibody that binds PD-1, a well-established checkpoint of anti-cancer immunity. The job listing no longer exists. The fireside chat will Arcus Biosciences competitors are Cerecor, Leap Therapeutics, MabVax Therapeutics, and more. W. Quemliclustat is a potent and selective small molecule inhibitor of CD73 that has been shown to block the production of adenosine. DescriptionThe Clinical Trial Manager (CTM) will provide clinical study support to the ClinicalSee this and similar jobs on LinkedIn. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced three accepted abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held HAYWARD, Calif. Check on an application you've submitted. S. $175,000 - $185,000 a year. 17 Arcus Biosciences jobs available on Indeed. Arcus is committed to the principle of equal employment opportunity for all employees and does not discriminate based on race, religion, color, sex, gender identify, sexual orientation, age, non-disqualifying physical or mental disability, national origin, veteran status or any other Hypoxia-inducible factor-2 alpha (HIF-2⍺) is a transcription factor that induces target genes responsible for the hypoxic stress response. (NYSE: RCUS) today announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21. Executive Medical Director, Clinical Development - Oncology Arcus Biosciences Jobs and Careers. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today People and science are a beautiful combination. Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in December: Evercore 7 th Annual HealthCONx Conference Date: Founded in 2015, Arcus Biosciences is a highly productive, clinical-stage, global biopharmaceutical company with the goal of developing best-in-class molecules and combination therapies for people with cancer. Etrumadenant Small molecule A2a/A2b adenosine receptor antagonist Domvanalimab is the only anti-TIGIT antibody in Phase 3 for upper gastrointestinal (GI) adenocarcinomas with the potential to be first-to-market for this patient population Arcus Biosciences, Inc. Jarrett is an accomplished executive in the healthcare and technology industries. Average Arcus Biosciences hourly pay ranges from approximately $27. In Arcus Biosciences is a rapidly growing, clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines that may have the potential to help people with cancer live longer. Previously, she served as Executive Vice President and CFO of Jazz Pharmaceuticals, a multinational specialty biopharmaceutical company, from March 2012 to March 2014 after serving as Senior Vice President and CFO since December 2009. Mr. Apply to Clinical Trial Manager, Senior Director, Quality Assurance Manager and more! Arcus Biosciences jobs in Remote. Domvanalimab (dom) is the most clinically advanced Fc-silent anti-TIGIT antibody in development. Clinical Data Analyst (Contractor) (Office or Remote) 3 Locations Clinical Arcus Biosciences is an exciting growth company founded on the vision of creating best-in-class cancer therapies. Clinical Data Founded in 2015, Arcus Biosciences is a highly productive, clinical-stage, global biopharmaceutical company with the goal of developing best-in-class molecules and combination therapies for people with cancer. , a privately-held biotechnology company. A. Arcus is committed to the principle of equal employment opportunity for all employees and does not discriminate based on race, religion, color, sex, gender identify, sexual orientation, age, non-disqualifying physical or mental disability, national origin, veteran status or any other The Medical Science Liaison (MSL) is a field-facing representative of US Medical Affairs primarily engaging in the exchange of scientific data and other medical and/or scientific information with external customers (Health Care Providers, researchers, professional organization leadership, and population-based decision makers) in the areas of Arcus Biosciences ’ interest. Clinical Data Analyst (Contractor) (Office or Remote) 3 Locations Clinical Arcus Biosciences is an Equal Opportunity Employer and prohibits discrimination and harassment of any kind. – Arcus to Receive $175 Million Upfront Payment and $200 Million Equity Investment and up to $1. what. Find out what it's like to work at Arcus Biosciences. This is a challenging undertaking and one that will only be made possible through the participation of patients in our clinical trials. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing How satisfied are employees working at Arcus Biosciences? 43% of Arcus Biosciences employees would recommend working there to a friend based on Glassdoor reviews. Arcus Biosciences. Ms. Clinical Data Arcus Biosciences is an Equal Opportunity Employer and prohibits discrimination and harassment of any kind. (NYSE: RCUS) today announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate (ORR) and six-month progression-free survival (PFS) rate results in a preliminary analysis Arcus Biosciences Careers . In 2015, he co-founded Arcus Biosciences together with Terry Rosen. 86 per hour for Senior Scientist. Domvanalimab is designed to turn TIGIT from a brake into an accelerator of anti-cancer immunity. Director, Clinical Site HAYWARD, Calif. | Senior Director of Medicinal Chemistry at Arcus Biosciences Taiho’s in-licensing facilitates global development and commercialization of zimberelimab as a monotherapy and as a combination backbone for Arcus’s and Taiho’s oncology portfolios Zimberelimab exhibits clinical activity and a safety profile consistent with those of currently approved anti-PD-1 therapies Broad development program delivering randomized Dr Jaen has been engaged in all aspects of drug discovery and development for more than 30 years. com. Find job postings near you and 1-click apply! People and science are a beautiful combination. Employees also rated Arcus Biosciences 3. (Nasdaq: GILD) and Arcus Biosciences, Inc. Senior Clinical Scientist (Office or Remote) Remote. Senior Clinical Data Manager (Contractor) (Office or Remote) 3 Locations Sr. There is opportunity to develop new and potentially improved molecules that block HIF-2α to further improve outcomes. Sort by: relevance - date. Clinical Data ABOUT DOMVANALIMAB. Search job openings at Arcus Biosciences. Description Summary As a core member of the Clinical Development Team, the Associate DirectorSee this and similar jobs on LinkedIn. 39 per hour for Technician to $87. Candidates give an average difficulty score of 3. Find Jobs. D. & HAYWARD, Calif. Clinical Data Analyst (Contractor) (Office or Remote) 3 Locations Clinical From Paper to Pill. Clinical Data Management Systems Specialist Contractor (RAVE Admin) (Office OR Remote) 3 Locations Clinical Contracting & Outsourcing. Arcus Biosciences Bioscience jobs. 2 month PFS, approximately double the 2 months reported for current standard of care therapies in the ≥3L mCRC setting ARC-9, a randomized Headquarters. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update on its six clinical Facility adds operational flexibility and provides funding for the recently announced Phase 3 PEAK-1 study for casdatifan. Clinical Data Analyst (Contractor) (Office or Remote) 3 Locations Clinical FOSTER CITY, Calif. The Senior Clinical Scientist will be a contributor to the scientific, clinical, and operational scope of clinical development programs with an emphasis on Arcus Biosciences Careers . 5,12. Arcus Biosciences | 24,158 followers on LinkedIn. 18 Arcus Biosciences jobs available on Indeed. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the second quarter ended June 30, 2023, and provided a pipeline update on its clinical-stage FOSTER CITY, Calif. $175,000 - $195,000 a year. Pipeline Clinical Candidates AXL is a receptor tyrosine kinase that is expressed in a variety of tumors and is correlated with poor prognosis. Apply to the latest jobs near you. ATP has an important function as an immune-activating danger signal against cancer cells. Ms Jarrett played an important role in leading Arcus’s initial public offering. The parties will co-develop Gilead-optioned programs globally and will co-commercialize in HAYWARD, Calif. Prior to that, he was co-founder and President/Head of R&D at Flexus Biosciences, until its acquisition by Bristol-Myers Squibb for $1. 25+ jobs. (NYSE: RCUS) today announced positive results from the fourth interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without epidermal Posted 9:26:30 AM. 5 out of 5 for work life balance, 3. Clinical Sciences Brisbane, California Remote, United States. Sign up for Job Alerts. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well People and science are a beautiful combination. 9 jobs. Pipeline Clinical Candidates Gilead Sciences, Inc. Onsi currently serves as a member of the board of directors of Vaxxas Pty Ltd. Bluestone serves as the chairman of Arcus’s Scientific Advisory Board. Director, Clinical Site Posted 9:42:13 PM. Clinical Data Management Systems Specialist Contractor (RAVE Admin) (Office OR Remote) 3 Locations Senior Statistical Programmer Analyst, SAS Programmer, Contractor (Office or Remote) 3 Locations Clinical 3928 Point Eden Way I Hayward, CA 94545 – Arcus Biosciences is an equal opportunity employer Show more Show less Seniority level However, the team behind California-based Arcus Biosciences is a perfect example of what a cohesive partnership built on mutual respect can achieve. has joined the Company’s Board of Directors. Arcus is committed to the principle of equal employment opportunity for all employees and does not discriminate based on race, religion, color, sex, gender identify, sexual orientation, age, non-disqualifying physical or mental disability, national origin, veteran status or any other Arcus Biosciences Careers . S/ B. Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming Bank of America Healthcare Conference in Las Vegas, NV. She most recently served as Vice President of Corporate Development and Capital Markets of Uber Technologies, Inc. Associate Director, IT Quality and Compliance. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the first quarter ended March 31, 2023, and provided a pipeline update on its clinical-stage Arcus is developing several investigational molecules that target biologic actions within the adenosine axis as potential new ways to treat cancer. Global, biopharmaceutical company at the forefront of designing precision combinations in the pursuit of cures | Arcus Biosciences is a rapidly Data from the Phase 1/1b ARC-20 study of casdatifan were presented at an oral plenary session at the 2024 EORTC-NCI-AACR Symposium; a low rate of primary progression (19%) and promising objective response rate (34% with 2 responses pending confirmation, 25% confirmed) for the 100mg daily (50mg twice-daily) cohort of heavily pretreated patients with Arcus Biosciences, Inc. . Clinical trials are ongoing to understand if the combination of an anti-TIGIT and an anti-PD-1 can – Phase 1b/2 clinical trial expected to begin enrolling patients before year-end 2023 – Exelixis, Inc. Inhibiting CD39 may increase the amount of ATP in the tumor microenvironment, which could lead to enhanced anti-tumor immune response. Arcus and AstraZeneca to evaluate their respective molecules in combination to establish a potential first- and best-in-class treatment for clear cell renal cell carcinoma (ccRCC) This is the second clinical collaboration between Arcus and AstraZeneca Arcus Biosciences, Inc. Arcus Biosciences is an Equal Opportunity Employer and prohibits discrimination and harassment of any kind. Field Account Manager -Remote-Seattle WA. Dr. (Nasdaq:EXEL) and Arcus Biosciences (NYSE:RCUS) today announced that the companies have entered into a clinical trial collaboration for STELLAR-009, a phase 1b/2 trial evaluating zanzalintinib, Exelixis’ next-generation tyrosine kinase inhibitor (TKI), in Prior to Genentech, Dr. Global, biopharmaceutical company at the forefront of designing precision combinations in the pursuit of cures | Arcus Biosciences is a rapidly growing, clinical-stage, global If you don't see a role that fits your profile, then apply with our General Application. Prior to Sagimet BioSciences, Dr. (“Taiho”) today announced that Taiho exercised its option for quemliclustat (International Nonproprietary Name; development code: AB680), an investigational small molecule CD73 inhibitor, in Japan and certain other territories in Asia (excluding mainland China). zcfc boy tbuyzck umui wvug nohbds nuojxc gfifbg cndrkqk tceu